Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03769103
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
- NCT03769103 ↗
- Active, not recruiting
- British Columbia Cancer Agency
- Focused
We haven't built an HCP commentary report on NCT03769103 (osimertinib in Lung Cancer Non-small Cell Stage IV) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03769103 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Lung Cancer Non-small Cell Stage IV; Brain Metastases
- Interventions
- Osimertinib; Stereotactic radiotherapy
- Arms
- SRS + Osimertinib · Active comparator
- Osimertinib alone · Experimental
- Enrollment
- 40
- Primary outcomes
- Intracranial progression free survival
- Sponsor
- British Columbia Cancer Agency with AstraZeneca, Princess Margaret Hospital, Canada, Sunnybrook Health Sciences Centre
- Start
- Mar 19, 2019
- Primary completion
- Apr 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03769103 · updated Oct 31, 2024
Publications
linked from the registry- Lee CK, Lefresne S, Soon YY, Robledo K, Nichol A, Sahgal A, Pinkham MB, Melosky B, Huang Y, McDermott R, Tham IWK, Parmar A, Tey JCS, Liu M, Solomon BJ, Sacher A, Leong CN, Laskin J, Koh WY, Menjak IB, Ang Y, Shultz DB, Low JL, Doherty M, Yong C, Lim MC, Tan AP, Soo RA, Hegi-Johnson F, Ho C. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026 May;21(5):103549. doi: 10.1016/j.jtho.2026.01.001. Epub 2026 Jan 12. PubMed 41534788